版本:
中国

BRIEF-Contravir Pharmaceuticals announced new data demonstrating clinical antiviral activity and safety, pharmacokinetic data of tenofovir exalidex

April 20 Contravir Pharmaceuticals Inc

* Contravir Pharmaceuticals - Announced new data demonstrating clinical antiviral activity and safety, pharmacokinetic data of tenofovir exalidex

* Contravir Pharma - Data demonstrated TXL, at all doses tested, resulted in lower systemic circulating levels of tenofovir in blood compared to viread

* Contravir Pharma - There were no serious adverse events (AES) or discontinuations; other safety parameters showed no patterns or relationship to TXL dose Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐